Trial Profile
68Ga-RM2 PET/MRI in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-contributory CT Scans
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 12 Apr 2023
Price :
$35
*
At a glance
- Drugs Gallium 68 RM2 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use
- 06 Apr 2023 Status changed from active, no longer recruiting to completed.
- 03 May 2022 Planned End Date changed from 1 Dec 2023 to 1 Nov 2022.
- 02 Mar 2022 Planned End Date changed from 1 Nov 2022 to 1 Dec 2023.